Chris Shibutani
Stock Analyst at Goldman Sachs
(3.20)
# 1,013
Out of 4,479 analysts
80
Total ratings
50%
Success rate
0.66%
Average return
Main Sectors:
29 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ERAS Erasca | Maintains: Buy | $7 → $4 | $2.32 | +72.41% | 4 | May 28, 2024 | |
| RVNC Revance Therapeutics | Maintains: Neutral | $9 → $8 | $2.42 | +230.58% | 5 | May 13, 2024 | |
| OGN Organon & Co. | Maintains: Neutral | $18 → $20 | $20.12 | -0.60% | 5 | May 6, 2024 | |
| UTHR United Therapeutics | Maintains: Neutral | $218 → $240 | $317.05 | -24.30% | 3 | May 3, 2024 | |
| LLY Eli Lilly | Maintains: Neutral | $650 → $723 | $906.71 | -20.26% | 6 | Apr 11, 2024 | |
| AMLX Amylyx Pharmaceuticals | Downgrades: Neutral | $40 → $4 | $1.74 | +129.89% | 7 | Mar 11, 2024 | |
| SDGR Schrödinger | Maintains: Neutral | $29 → $26 | $20.33 | +27.89% | 1 | Mar 1, 2024 | |
| BNTX BioNTech SE | Maintains: Neutral | $113 → $100 | $78.76 | +26.97% | 6 | Feb 28, 2024 | |
| RPRX Royalty Pharma | Maintains: Buy | $56 → $50 | $25.88 | +93.20% | 2 | Feb 20, 2024 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $134 → $153 | $137.49 | +11.28% | 2 | Jan 25, 2024 | |
| ABBV AbbVie | Upgrades: Buy | $173 | $165.96 | +4.24% | 4 | Dec 11, 2023 | |
| NKTR Nektar Therapeutics | Upgrades: Outperform | n/a | $1.17 | - | 4 | Nov 9, 2023 | |
| MCRB Seres Therapeutics | Maintains: Sell | $4 → $1.25 | $0.70 | +78.32% | 2 | Nov 3, 2023 | |
| BMY Bristol-Myers Squibb Company | Maintains: Buy | $81 → $69 | $40.45 | +70.58% | 2 | Oct 30, 2023 | |
| SNDX Syndax Pharmaceuticals | Initiates: Buy | $30 | $20.66 | +45.21% | 2 | Oct 11, 2023 | |
| INVA Innoviva | Maintains: Neutral | $15 → $13 | $16.50 | -21.21% | 2 | Mar 3, 2023 | |
| RVMD Revolution Medicines | Maintains: Neutral | $20 → $23 | $37.38 | -38.47% | 3 | Mar 1, 2023 | |
| VTYX Ventyx Biosciences | Initiates: Buy | $50 | $2.14 | +2,236.45% | 1 | Dec 19, 2022 | |
| KYMR Kymera Therapeutics | Maintains: Buy | $40 → $52 | $30.22 | +72.07% | 2 | Dec 16, 2022 | |
| PFE Pfizer | Upgrades: Buy | $47 → $60 | $27.83 | +115.59% | 2 | Dec 13, 2022 | |
| TRDA Entrada Therapeutics | Maintains: Neutral | $13 → $18 | $14.00 | +28.57% | 4 | Nov 8, 2022 | |
| EXAI Exscientia | Maintains: Buy | $23 → $20 | $5.10 | +292.16% | 2 | May 24, 2022 | |
| ALKS Alkermes | Initiates: Buy | $35 | $24.19 | +44.69% | 1 | Apr 20, 2022 | |
| JNJ Johnson & Johnson | Maintains: Neutral | $163 → $181 | $146.03 | +23.95% | 2 | Apr 12, 2022 | |
| TNGX Tango Therapeutics | Initiates: Buy | n/a | $8.11 | - | 1 | Sep 7, 2021 | |
| RPTX Repare Therapeutics | Initiates: Outperform | n/a | $3.24 | - | 1 | Jul 14, 2020 | |
| ARDX Ardelyx | Initiates: Outperform | n/a | $5.28 | - | 1 | Feb 10, 2020 | |
| PBYI Puma Biotechnology | Downgrades: Market Perform | n/a | $3.10 | - | 2 | Jan 24, 2018 | |
| RDUS Radius Health | Downgrades: Market Perform | n/a | $14.67 | - | 1 | May 2, 2017 |
Erasca
May 28, 2024
Maintains: Buy
Price Target: $7 → $4
Current: $2.32
Upside: +72.41%
Revance Therapeutics
May 13, 2024
Maintains: Neutral
Price Target: $9 → $8
Current: $2.42
Upside: +230.58%
Organon & Co.
May 6, 2024
Maintains: Neutral
Price Target: $18 → $20
Current: $20.12
Upside: -0.60%
United Therapeutics
May 3, 2024
Maintains: Neutral
Price Target: $218 → $240
Current: $317.05
Upside: -24.30%
Eli Lilly
Apr 11, 2024
Maintains: Neutral
Price Target: $650 → $723
Current: $906.71
Upside: -20.26%
Amylyx Pharmaceuticals
Mar 11, 2024
Downgrades: Neutral
Price Target: $40 → $4
Current: $1.74
Upside: +129.89%
Schrödinger
Mar 1, 2024
Maintains: Neutral
Price Target: $29 → $26
Current: $20.33
Upside: +27.89%
BioNTech SE
Feb 28, 2024
Maintains: Neutral
Price Target: $113 → $100
Current: $78.76
Upside: +26.97%
Royalty Pharma
Feb 20, 2024
Maintains: Buy
Price Target: $56 → $50
Current: $25.88
Upside: +93.20%
Neurocrine Biosciences
Jan 25, 2024
Maintains: Buy
Price Target: $134 → $153
Current: $137.49
Upside: +11.28%
AbbVie
Dec 11, 2023
Upgrades: Buy
Price Target: $173
Current: $165.96
Upside: +4.24%
Nektar Therapeutics
Nov 9, 2023
Upgrades: Outperform
Price Target: n/a
Current: $1.17
Upside: -
Seres Therapeutics
Nov 3, 2023
Maintains: Sell
Price Target: $4 → $1.25
Current: $0.70
Upside: +78.32%
Bristol-Myers Squibb Company
Oct 30, 2023
Maintains: Buy
Price Target: $81 → $69
Current: $40.45
Upside: +70.58%
Syndax Pharmaceuticals
Oct 11, 2023
Initiates: Buy
Price Target: $30
Current: $20.66
Upside: +45.21%
Innoviva
Mar 3, 2023
Maintains: Neutral
Price Target: $15 → $13
Current: $16.50
Upside: -21.21%
Revolution Medicines
Mar 1, 2023
Maintains: Neutral
Price Target: $20 → $23
Current: $37.38
Upside: -38.47%
Ventyx Biosciences
Dec 19, 2022
Initiates: Buy
Price Target: $50
Current: $2.14
Upside: +2,236.45%
Kymera Therapeutics
Dec 16, 2022
Maintains: Buy
Price Target: $40 → $52
Current: $30.22
Upside: +72.07%
Pfizer
Dec 13, 2022
Upgrades: Buy
Price Target: $47 → $60
Current: $27.83
Upside: +115.59%
Entrada Therapeutics
Nov 8, 2022
Maintains: Neutral
Price Target: $13 → $18
Current: $14.00
Upside: +28.57%
Exscientia
May 24, 2022
Maintains: Buy
Price Target: $23 → $20
Current: $5.10
Upside: +292.16%
Alkermes
Apr 20, 2022
Initiates: Buy
Price Target: $35
Current: $24.19
Upside: +44.69%
Johnson & Johnson
Apr 12, 2022
Maintains: Neutral
Price Target: $163 → $181
Current: $146.03
Upside: +23.95%
Tango Therapeutics
Sep 7, 2021
Initiates: Buy
Price Target: n/a
Current: $8.11
Upside: -
Repare Therapeutics
Jul 14, 2020
Initiates: Outperform
Price Target: n/a
Current: $3.24
Upside: -
Ardelyx
Feb 10, 2020
Initiates: Outperform
Price Target: n/a
Current: $5.28
Upside: -
Puma Biotechnology
Jan 24, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $3.10
Upside: -
Radius Health
May 2, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $14.67
Upside: -